NivolumabImmune-mediated hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1789卷 / 1期

关键词：

D O I：

10.1007/s40278-020-74545-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：195 / 195

相关论文

共 50 条

[31] Ipilimumab/nivolumabImmune mediated hepatitis: case report
Reactions Weekly, 2019, 1757 (1) : 176 - 176
[32] NivolumabImmune-mediated gastroduodenitis with ulceration leading to unremitting nausea and vomiting: case report
Reactions Weekly, 2017, 1673 (1) : 278 - 278
[33] Ipilimumab/nivolumabImmune mediated hepatitis: case report
Reactions Weekly, 2021, 1869 (1) : 193 - 193
[34] NivolumabImmune-mediated liver toxicity and end-stage liver disease: case report
Reactions Weekly, 2021, 1836 (1) : 595 - 595
[35] Cabozantinib/ipilimumab/nivolumabImmune-mediated enteritis, perianal abscess and perianal fistulas: case report
Reactions Weekly, 2025, 2043 (1) : 89 - 89
[36] NivolumabImmune mediated myocarditis, rhabdomyolysis and hepatitis: case report
Reactions Weekly, 2023, 1949 (1) : 344 - 344
[37] Ipilimumab/nivolumabImmune-mediated colitis complicated by hypokalaemia and QT interval prolongation: case report
Reactions Weekly, 2020, 1790 (1) : 140 - 140
[38] NivolumabImmune-mediated colitis, enteritis and neobladder pouchitis
Reactions Weekly, 2024, 2015 (1) : 339 - 339
[39] Ipilimumab/NivolumabImmune-mediated hypophysitis and thyroid dysfunction: 2 case reports
Reactions Weekly, 2017, 1675 (1) : 138 - 138
[40] Ipilimumab/nivolumabImmune-mediated enterocolitis, pancreatitis and lack of efficacy: 2 case reports
Reactions Weekly, 2024, 2024 (1) : 242 - 242

← 1 2 3 4 5 →